Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1

Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1
The Phase 1/2 trial evaluating Celsion’s investigational DNA-based immunotherapy GEN-1 as an add-on to standard chemotherapy for localized treatment of ovarian cancer has started dosing patients. GEN-1 is a nanoparticle containing the DNA sequence for the pro-inflammatory protein interleukin-12 (IL-12). When delivered to the tumor, GEN-1 induces a sustained production and release of IL-12, triggering an immune response

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *